China's drug market will reach 1.71 trillion yuan

The overall growth rate of drug terminal consumption in 2017 will be 6%, and the size of China's drug market will reach 1.71 trillion yuan in 2018, an increase of 8.3% over 2017, and the growth rate will pick up. Recently, china's largest annual meeting of the pharmaceutical industry - 2018 China Health Industry Cooperation and Development Forum (Sipu), the organizers of China Health Information President Wu Han introduced, of which the growth rate of physical pharmacies is 8.5%, including non-drugs 7.5%.
report from the General Assembly shows that since 2017, in the context of social and economic stability, the biggest factor affecting the drug market is the new health care reform policies that have been enacted and will continue to be enacted.
Overall, the rising health needs of residents, the aging of the population structure, the large number of chronically ill groups and other factors, so that the drug market will show sustained overall growth, but the growth rate, growth terminal, growth category, these three aspects are significantly affected by the new medical reform policy.drug retailing is also affected by the vaccine incident
in 2017, the total size of the entire Chinese drug market (excluding retail medicines) reached 1580 billion yuan, an increase of 6.0% over 2016. With a five-year compound growth rate of 7.5%, urban primary and retail pharmacies grew slightly faster than large hospitals. Drug prices are under pressure to go down because of the full implementation of the drug zero rate and the impact of health insurance price negotiations.
business environment is more severe. According to the comprehensive competitiveness survey of Zhongkang Information, the rental cost of the top 100 chains increased by 10.7% in 2017 compared with the previous year, while labor costs increased by 16.9%, but the gross margin and net profit margin were lower than the operating level in 2012.
meeting, Xie Zilong, chairman of the People's Big Pharmacy Chain Co., Ltd., said, "With the reform of the state drug regulatory sector, increased competition in the industry and capital entry and other factors, the pharmaceutical industry is facing changes."
in addition, Xie Zilong also said that the recent vaccine incident and the drug retail industry, "city fire, fish and pond fish", I believe that the vaccine incident on our entire pharmaceutical industry, pharmaceutical industry, drug retail industry is huge, drug regulatory system will be more and more attention by the state.negative growth in Chinese-made injectables
the growth rate of retail drug sales, growth terminals and growth categories were all significantly affected by the new medical reform policy.
Wu Han, president of Zhongkang Information, said that since 2014, provinces have been fully implementing the zero-rate policy for drugs in public hospitals, and by September 2017, public hospitals in all provinces of the country have been fully implementing the zero-rate policy, resulting in a 17-year growth rate of only 1.5% and 3.4% in urban and county-level hospitals.
the increase in the proportion of other drugs, charging by disease, deepening the reform of medical insurance payments, limiting the growth rate of medical expenses, and expanding and deepening the comprehensive reform of county-level public hospitals all have an impact on the growth rate of the scale of grade hospitals.
But stimulated by the continued growth of residents' medical and health needs, the expansion of medical insurance coverage and the expansion of the medical insurance catalogue, the growth rate of urban grade hospitals is forecast to reach 6.5% in 2018 and that of county levels will reach 6.7%, which has picked up.
affected by policies such as the list of complementary drugs, controlling the proportion of drugs and limiting the growth rate of medical expenses, the share of major varieties of grade hospitals, such as large infusions, auxiliary drugs and Chinese medicine injections, declined.
Among the major Chinese medicine injections, heart disease treatment drugs, anti-tumor drugs and cough and cold medications (mainly anti-inflammatory Chinese medicine injections) all showed negative growth in 2017, with cough and cold medications falling by nearly 10%, and the decline in cough and cold medications is expected to expand further in 2018.Chronic disease drug use to grass-roots and retail channels
In 2017, the market size of urban primary hospitals reached 95.1 billion yuan, up 8.9% YoY, with a compound growth rate of 16.0%, and is expected to grow at a rate of 14.1% in 2018, with the drug use reaching 108.5 billion yuan, a compound growth rate of 10.2%. In 2017, the rural primary hospital market reached 71.2 billion yuan, up 3.8% YoY, with a compound growth rate of 7.2%, and is expected to reach 75 billion yuan in 18 years, an increase of 5.4%.
the growth of primary health care institutions, mainly due to the initial results of the initiative of graded diagnosis and treatment, while the provinces have gradually liberalized restrictions on primary drug use.
2015-2017, the share of chronic drug use in grade hospitals has gradually declined, and the size and share of primary health care institutions and retail pharmacies has been increasing, with the growth rate of chronic drug use in retail pharmacies exceeding 10%.
prescription outflow is a hot topic of recent discussion. Wu Han said that the "Zhangzhou model" as an example, the establishment of hospitals and pharmacies prescription information sharing platform, patients can choose to share the platform outside the hospital pharmacy to collect medicine. Since the launch of the prescription information sharing platform, the proportion of chronically ill drugs used in retail pharmacies in Zhangzhou City has increased steadily compared to 2016, the proportion of chronically ill drugs has reached its highest level in nearly two years since the expansion of access in November 2017, and the proportion of prescriptions for special chronic diseases in health insurance outpatient clinics will be trialled in July 2018, and there is reason to believe that the proportion will be further increased. Establishing a prescription information sharing platform for hospitals and pharmacies is an effective way to promote prescription outflow.prospects for the growth of anti-tumor drugs
The share of anti-tumor drugs continues to grow, especially the key anti-tumor drugs listed in the health insurance list will increase significantly in 2018. Although the drug will face pressure to reduce prices after being included in the health insurance list, patient demand and Medicare reimbursement policies will further expand the use of the drug and increase the use of the drug. In the case of new anti-tumor drugs such as protein kinase inhibitors and monoants, the average growth rate of grade hospitals in 2014-2018 was between 17% and 18%.
Due to the impact of health insurance control fees, bidding and procurement price limits, long bidding process and other factors, some new specialty drugs choose to be the first to be listed in retail pharmacies, has been listed high-priced drugs such as anti-tumor drugs also began to transfer to retail pharmacies, 2014 The average growth of retail pharmacies from 2018 to 2018 is as high as 40%-42%, with retail pharmacies' protein kinase inhibitors reaching 25.8% in 2017 and expected to exceed 30% in 18 years. Retail pharmacies, especially the emerging DTP pharmacy, a drug model that sells directly to patients, editor's note, will be an important channel for high-priced drugs such as new drugs and new anti-tumor drugs. Consistency evaluation test continues, generic drug positives are beginning to show
Data from Zhongkang Information show that as of May 2018, there have been 21 varieties, confirmed that at least one generic drug through the consistent evaluation, 45 (standard) generic drugs passed, or as if through the consistency evaluation.
-related generic name size is expected to grow significantly in 2018. As more and more local enterprises pass the consistency evaluation, the share and price of generic drugs will be put under further downswing pressure. In the case of clopidogrere, for example, the share of original products is expected to decline in 2018, with a further increase in the share of generics that have passed the conformity evaluation, while the share of generics that have not passed the conformity evaluation has increased only slightly. In terms of prices, both the original and generic drug prices have declined, of which generic drugs have declined significantly. It is a long-term trend to replace imported primary drugs with drugs evaluated by consistency. (Southern Daily News)